美诺华子公司获得利奥西呱片药品注册证书

Core Viewpoint - Meihua (603538.SH) announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Liosiguat tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option in the market [1] Group 1 - The drug Liosiguat is indicated for the treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH) [1]